Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
- Author
- HEROLD, K. C1 ; GITELMAN, S. E2 ; MICHELS, A. W4 ; DZIURA, J6 ; BLUESTONE, J. A2 ; WILLI, S. M3 ; GOTTLIEB, P. A4 ; WALDRON-LYNCH, F1 ; DEVINE, L1 ; SHERR, J5 ; ROSENTHAL, S. M2 ; ADI, S2 ; JALALUDIN, M. Y3
[1] Department of Immunobiology and Internal Medicine, Yale University, 300 George St, 353E, New Haven, CT 06511, United States
[2] Department of Pediatrics and Internal Medicine, University of California at San Francisco, San Francisco, CA, United States
[3] Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, United States
[4] Department of Internal Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States
[5] Department of Pediatrics, Yale University, New Haven, CT, United States
[6] Department of Emergency Medicine, Yale University, New Haven, CT, United States - Source
Diabetologia (Berlin). 2013, Vol 56, Num 2, pp 391-400, 10 p ; ref : 31 ref
- ISSN
- 0012-186X
- Scientific domain
- Endocrinology; Nutrition, obesity, metabolic disorders
- Publisher
- Springer, Heidelberg
- Publication country
- Germany
- Document type
- Article
- Language
- English
- Author keyword
- Autoimmunity Immune therapy Type 1 diabetes
- Keyword (fr)
- Autoimmunité Diabète de type 1 Peptide C Traitement Endocrinopathie Immunopathologie Maladie autoimmune
- Keyword (en)
- Autoimmunity Type 1 diabetes C-Peptide Treatment Endocrinopathy Immunopathology Autoimmune disease
- Keyword (es)
- Autoinmunidad Diabetes de tipo 1 Péptido C Tratamiento Endocrinopatía Inmunopatología Enfermedad autoinmune
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B21 Endocrinopathies / 002B21E Endocrine pancreas. Apud cells (diseases) / 002B21E01 Diabetes. Impaired glucose tolerance / 002B21E01A Etiopathogenesis. Screening. Investigations. Target tissue resistance
- Discipline
- Endocrinopathies
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27531367
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s00125-012-2753-4 
https://dx.doi.org/10.1007/s00125-012-2753-4
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00125-012-2753-4\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Diabetologia (Berlin)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Diabetologia (Berl.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"56\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"391\";s:8:\"\u0000*\u0000epage\";s:3:\"400\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-186X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HEROLD\";s:10:\"\u0000*\u0000aufirst\";s:4:\"K. C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:14:\"GITELMAN, S. E\";i:1;s:13:\"MICHELS, A. W\";i:2;s:9:\"DZIURA, J\";i:3;s:15:\"BLUESTONE, J. A\";i:4;s:11:\"WILLI, S. M\";i:5;s:14:\"GOTTLIEB, P. A\";i:6;s:16:\"WALDRON-LYNCH, F\";i:7;s:9:\"DEVINE, L\";i:8;s:8:\"SHERR, J\";i:9;s:15:\"ROSENTHAL, S. M\";i:10;s:6:\"ADI, S\";i:11;s:15:\"JALALUDIN, M. Y\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00125-012-2753-4\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Diabetologia (Berlin)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Diabetologia (Berl.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"56\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"391\";s:8:\"\u0000*\u0000epage\";s:3:\"400\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-186X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HEROLD\";s:10:\"\u0000*\u0000aufirst\";s:4:\"K. C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:14:\"GITELMAN, S. E\";i:1;s:13:\"MICHELS, A. W\";i:2;s:9:\"DZIURA, J\";i:3;s:15:\"BLUESTONE, J. A\";i:4;s:11:\"WILLI, S. M\";i:5;s:14:\"GOTTLIEB, P. A\";i:6;s:16:\"WALDRON-LYNCH, F\";i:7;s:9:\"DEVINE, L\";i:8;s:8:\"SHERR, J\";i:9;s:15:\"ROSENTHAL, S. M\";i:10;s:6:\"ADI, S\";i:11;s:15:\"JALALUDIN, M. Y\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00125-012-2753-4\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00125-012-2753-4\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Diabetologia (Berlin)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Diabetologia (Berl.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"56\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"391\";s:8:\"\u0000*\u0000epage\";s:3:\"400\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-186X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HEROLD\";s:10:\"\u0000*\u0000aufirst\";s:4:\"K. C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:14:\"GITELMAN, S. E\";i:1;s:13:\"MICHELS, A. W\";i:2;s:9:\"DZIURA, J\";i:3;s:15:\"BLUESTONE, J. A\";i:4;s:11:\"WILLI, S. M\";i:5;s:14:\"GOTTLIEB, P. A\";i:6;s:16:\"WALDRON-LYNCH, F\";i:7;s:9:\"DEVINE, L\";i:8;s:8:\"SHERR, J\";i:9;s:15:\"ROSENTHAL, S. M\";i:10;s:6:\"ADI, S\";i:11;s:15:\"JALALUDIN, M. Y\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00125-012-2753-4\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Diabetologia (Berlin)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Diabetologia (Berl.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"56\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"391\";s:8:\"\u0000*\u0000epage\";s:3:\"400\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-186X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HEROLD\";s:10:\"\u0000*\u0000aufirst\";s:4:\"K. C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:14:\"GITELMAN, S. E\";i:1;s:13:\"MICHELS, A. W\";i:2;s:9:\"DZIURA, J\";i:3;s:15:\"BLUESTONE, J. A\";i:4;s:11:\"WILLI, S. M\";i:5;s:14:\"GOTTLIEB, P. A\";i:6;s:16:\"WALDRON-LYNCH, F\";i:7;s:9:\"DEVINE, L\";i:8;s:8:\"SHERR, J\";i:9;s:15:\"ROSENTHAL, S. M\";i:10;s:6:\"ADI, S\";i:11;s:15:\"JALALUDIN, M. Y\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00125-012-2753-4\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Diabetologia (Berlin)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Diabetologia (Berl.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"56\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"391\";s:8:\"\u0000*\u0000epage\";s:3:\"400\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-186X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HEROLD\";s:10:\"\u0000*\u0000aufirst\";s:4:\"K. C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:14:\"GITELMAN, S. E\";i:1;s:13:\"MICHELS, A. W\";i:2;s:9:\"DZIURA, J\";i:3;s:15:\"BLUESTONE, J. A\";i:4;s:11:\"WILLI, S. M\";i:5;s:14:\"GOTTLIEB, P. A\";i:6;s:16:\"WALDRON-LYNCH, F\";i:7;s:9:\"DEVINE, L\";i:8;s:8:\"SHERR, J\";i:9;s:15:\"ROSENTHAL, S. M\";i:10;s:6:\"ADI, S\";i:11;s:15:\"JALALUDIN, M. Y\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
